382 related articles for article (PubMed ID: 25534017)
1. Treatment outcomes in a cohort of patients with mucosal-predominant pemphigus vulgaris.
Ojaimi S; O'Connor K; Lin MW; Schifter M; Fulcher DA
Intern Med J; 2015 Mar; 45(3):284-92. PubMed ID: 25534017
[TBL] [Abstract][Full Text] [Related]
2. Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil.
Biot Sdel R; Franco JP; Lima RB; Pereira HN; Marques LP; Martins CJ
An Bras Dermatol; 2014; 89(6):980-4. PubMed ID: 25387507
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris.
Chams-Davatchi C; Esmaili N; Daneshpazhooh M; Valikhani M; Balighi K; Hallaji Z; Barzegari M; Akhyani M; Ghodsi SZ; Seirafi H; Nazemi MJ; Mortazavi H; Mirshams-Shahshahani M
J Am Acad Dermatol; 2007 Oct; 57(4):622-8. PubMed ID: 17583373
[TBL] [Abstract][Full Text] [Related]
4. Where does rituximab fit in the treatment of autoimmune mucocutaneous blistering skin disease?
Nigam R; Levitt J
J Drugs Dermatol; 2012 May; 11(5):622-5. PubMed ID: 22527431
[TBL] [Abstract][Full Text] [Related]
5. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus.
Beissert S; Werfel T; Frieling U; Böhm M; Sticherling M; Stadler R; Zillikens D; Rzany B; Hunzelmann N; Meurer M; Gollnick H; Ruzicka T; Pillekamp H; Junghans V; Luger TA
Arch Dermatol; 2006 Nov; 142(11):1447-54. PubMed ID: 17116835
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil as adjuvant in pemphigus vulgaris.
Sarma N; Ghosh S
Indian J Dermatol Venereol Leprol; 2007; 73(5):348-50. PubMed ID: 17921620
[TBL] [Abstract][Full Text] [Related]
7. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.
Kim MR; Kim HC; Kim SC
Dermatology; 2011; 223(2):182-8. PubMed ID: 22025028
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil as a first-line steroid-sparing agent in the treatment of pemphigus vulgaris.
Vyas N; Patel NS; Cohen GF
J Drugs Dermatol; 2013 Feb; 12(2):210-6. PubMed ID: 23377396
[TBL] [Abstract][Full Text] [Related]
9. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease?
Miehsler W; Reinisch W; Moser G; Gangl A; Vogelsang H
Am J Gastroenterol; 2001 Mar; 96(3):782-7. PubMed ID: 11280551
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate is effective in the treatment of pemphigus vulgaris.
Enk AH; Knop J
Arch Dermatol; 1999 Jan; 135(1):54-6. PubMed ID: 9923781
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Pemphigus Vulgaris and Foliaceus with Adjuvant Rituximab Compared to Immunosuppression Alone: Real-Life Experience.
Snast I; Spitzer L; Hodak E; Levi A; Mimouni D; Leshem YA
Dermatology; 2021; 237(2):179-184. PubMed ID: 32756069
[TBL] [Abstract][Full Text] [Related]
12. Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and prednisone.
Scheinfeld N
J Dermatolog Treat; 2007; 18(4):243-5. PubMed ID: 17671884
[TBL] [Abstract][Full Text] [Related]
13. Recalcitrant pemphigus vulgaris responding to systemic tacrolimus.
Büsing V; Kern JS; Bruckner-Tuderman L; Hofmann SC
Dermatology; 2010; 221(2):122-6. PubMed ID: 20587990
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: The Mycophenolate Mofetil Acute Renal Rejection Study Group.
Transplantation; 1998 Jan; 65(2):235-41. PubMed ID: 9458021
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis.
Sahin GM; Sahin S; Kiziltas S; Masatlioglu S; Oguz F; Ergin H
Ren Fail; 2008; 30(9):865-9. PubMed ID: 18925525
[TBL] [Abstract][Full Text] [Related]
16. [Therapy of pemphigus].
van Beek N; Zillikens D; Schmidt E
Hautarzt; 2019 Apr; 70(4):243-253. PubMed ID: 30887081
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases.
Grundmann-Kollmann M; Korting HC; Behrens S; Kaskel P; Leiter U; Krähn G; Kerscher M; Peter RU
J Am Acad Dermatol; 1999 Jun; 40(6 Pt 1):957-60. PubMed ID: 10365927
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study.
Ioannides D; Apalla Z; Lazaridou E; Rigopoulos D
J Eur Acad Dermatol Venereol; 2012 Jul; 26(7):855-60. PubMed ID: 21752101
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil, azathioprine and methotrexate usage in paediatric anti-NMDAR encephalitis: A systematic literature review.
Nosadini M; Mohammad SS; Toldo I; Sartori S; Dale RC
Eur J Paediatr Neurol; 2019 Jan; 23(1):7-18. PubMed ID: 30318435
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the therapeutic benefit of oral prednisolone and common adjuvant therapy in stage II of randomized controlled trial study for management of pemphigus vulgaris.
Esmaili N; Chams-Davatchi C; Valikhani M; Daneshpazhooh M; Toosi S; Karimi A; Mortazavi H
Arch Iran Med; 2014 Sep; 17(9):626-8. PubMed ID: 25204479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
